The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy
DR Principe, PW Underwood, M Korc… - Frontiers in …, 2021 - frontiersin.org
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …
[Retracted] Apoptosis and Molecular Targeting Therapy in Cancer
M Hassan, H Watari, A AbuAlmaaty… - BioMed research …, 2014 - Wiley Online Library
Apoptosis is the programmed cell death which maintains the healthy survival/death balance
in metazoan cells. Defect in apoptosis can cause cancer or autoimmunity, while enhanced …
in metazoan cells. Defect in apoptosis can cause cancer or autoimmunity, while enhanced …
Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells
KE Richards, AE Zeleniak, ML Fishel, J Wu… - Oncogene, 2017 - nature.com
Cancer-associated fibroblasts (CAFs) comprise the majority of the tumor bulk of pancreatic
ductal adenocarcinomas (PDACs). Current efforts to eradicate these tumors focus …
ductal adenocarcinomas (PDACs). Current efforts to eradicate these tumors focus …
Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
L de Sousa Cavalcante, G Monteiro - European journal of pharmacology, 2014 - Elsevier
Gemcitabine is the first-line treatment for pancreatic adenocarcinoma, but is increasingly
used to treat breast, bladder, and non-small cell lung cancers. Despite such broad use …
used to treat breast, bladder, and non-small cell lung cancers. Despite such broad use …
Molecular mechanisms of drug resistance
DB Longley, PG Johnston - The Journal of Pathology: A Journal …, 2005 - Wiley Online Library
Resistance to chemotherapy limits the effectiveness of anti‐cancer drug treatment. Tumours
may be intrinsically drug‐resistant or develop resistance to chemotherapy during treatment …
may be intrinsically drug‐resistant or develop resistance to chemotherapy during treatment …
Genetics and biology of pancreatic ductal adenocarcinoma
AF Hezel, AC Kimmelman, BZ Stanger… - Genes & …, 2006 - genesdev.cshlp.org
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the
United States with a median survival of< 6 mo and a dismal 5-yr survival rate of 3%–5%. The …
United States with a median survival of< 6 mo and a dismal 5-yr survival rate of 3%–5%. The …
Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy
Activation of transcription factor NF-κB is frequently encountered in tumor cells and
contributes to aggressive tumor growth and resistance to chemotherapy and ionizing …
contributes to aggressive tumor growth and resistance to chemotherapy and ionizing …
Nuclear factor-κB inhibitors as sensitizers to anticancer drugs
C Nakanishi, M Toi - Nature Reviews Cancer, 2005 - nature.com
The cytotoxicity of chemotherapeutic agents is attributed to apoptosis. Acquired resistance to
the effects of chemotherapy has emerged as a significant impediment to effective cancer …
the effects of chemotherapy has emerged as a significant impediment to effective cancer …
Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of …
AB Kunnumakkara, S Guha, S Krishnan… - Cancer research, 2007 - AACR
Gemcitabine is currently the best treatment available for pancreatic cancer, but the disease
develops resistance to the drug over time. Agents that can either enhance the effects of …
develops resistance to the drug over time. Agents that can either enhance the effects of …
[HTML][HTML] Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells
N Chehl, G Chipitsyna, Q Gong, CJ Yeo, HA Arafat - Hpb, 2009 - Elsevier
Background Both hereditary and sporadic forms of chronic pancreatitis are associated with
an increased risk of developing pancreatic ductal adenocarcinoma (PDA). Inflammation has …
an increased risk of developing pancreatic ductal adenocarcinoma (PDA). Inflammation has …